Fidelity Investments
ACET icon

Fidelity Investments’s Adicet Bio ACET Stock Holding History

Fidelity Investments’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34
Closed -$286 – 5413
2025
Q4 		$286 Sell
34
-15
-31% -$166 ﹤0.01% 5187
2025
Q3 		$629 Sell
49
-15,250
-100% -$180K ﹤0.01% 5071
2025
Q2 		$149K Sell
15,299
-263
-2% -$2.77K ﹤0.01% 3435
2025
Q1 		$188K Sell
15,562
-3,557
-19% -$50.9K ﹤0.01% 3272
2024
Q4 		$294K Buy
19,119
+1,858
+11% +$35.1K ﹤0.01% 3111
2024
Q3 		$398K Buy
17,261
+4,119
+31% +$92.2K ﹤0.01% 2948
2024
Q2 		$254K Buy
13,142
+1,004
+8% +$26.9K ﹤0.01% 2955
2024
Q1 		$456K Buy
12,138
+3,643
+43% +$151K ﹤0.01% 2755
2023
Q4 		$257K Sell
8,495
-5
-0.1% -$109 ﹤0.01% 2881
2023
Q3 		$186K Buy
8,500
+4,058
+91% +$143K ﹤0.01% 2909
2023
Q2 		$173K Buy
4,442
+4,339
+4,213% +$383K ﹤0.01% 2997
2023
Q1 		$9.52K Sell
103
-35,118
-100% -$4.41M ﹤0.01% 4147
2022
Q4 		$5.04M Sell
35,221
-15,363
-30% -$3.83M ﹤0.01% 2118
2022
Q3 		$11.5M Buy
50,584
+13
+0% +$3.3K ﹤0.01% 1837
2022
Q2 		$11.8M Buy
50,571
+15,036
+42% +$3.3M ﹤0.01% 1886
2022
Q1 		$11.4M Buy
35,535
+19,050
+116% +$4.38M ﹤0.01% 2060
2021
Q4 		$4.61M Buy
+16,485
New +$2.83M ﹤0.01% 2385
2021
Q1 		– Sell
-2
Closed – – 3931
2020
Q4 		$0 Buy
+2
New +$410 ﹤0.01% 3782
2019
Q4 		– Sell
-2,755
Closed -$2.73M – 3738
2019
Q3 		$2.73M Buy
2,755
+9
+0.3% +$10K ﹤0.01% 2199
2019
Q2 		$3.14M Sell
2,746
-466
-15% -$422K ﹤0.01% 2220
2019
Q1 		$2.45M Buy
+3,212
New +$2.92M ﹤0.01% 2249
2018
Q3 		– Sell
-18,046
Closed -$18.1M – 3499
2018
Q2 		$18.1M Sell
18,046
-8,190
-31% -$8.82M ﹤0.01% 1756
2018
Q1 		$27.3M Buy
+26,236
New +$48.1M ﹤0.01% 1579

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fidelity Investments's ACET Position: Q1 2026 in Review

Fidelity Investments sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 34 shares — an estimated $286 sold.

Fidelity Investments first reported a position in ACET in Q1 2018 and held it in 23 quarters. The position peaked at $27.3M in Q1 2018. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Fidelity Investments reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 34 Adicet Bio shares in Q1 2026, an estimated $286.
  • Fidelity Investments first reported a position in Adicet Bio in Q1 2018 and held it in 23 quarters.
  • Fidelity Investments's Adicet Bio position peaked at $27.3M in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.